Skip to main content
Erschienen in: Cancer Causes & Control 12/2017

13.10.2017 | Original paper

Treatment and survival disparities by ethnicity in New Zealand women with stage I–III breast cancer tumour subtypes

verfasst von: Ross Lawrenson, Chunhuan Lao, Ian Campbell, Vernon Harvey, Sanjeewa Seneviratne, Melissa Edwards, Mark Elwood, Nina Scott, Jacquie Kidd, Diana Sarfati, Marion Kuper-Hommel

Erschienen in: Cancer Causes & Control | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aims to look at the distribution of different subtypes of stage I–III breast cancer in Māori and Pacific versus non-Māori/Pacific women, and to examine cancer outcomes by ethnicity within these different subtypes.

Method

This study included 9,015 women diagnosed with stage I–III breast cancer between June 2000 and May 2013, recorded in the combined Waikato and Auckland Breast Cancer Registers, who had complete data on ER, PR and HER2 status. Five ER/PR/HER2 subtypes were defined. Kaplan–Meier method and Cox proportional hazards model were used to examine ethnic disparities in breast cancer-specific survival.

Results

Of the 9,015 women, 891 were Māori, 548 were Pacific and 7,576 others. Both Māori and Pacific women were less likely to have triple negative breast cancer compared to others (8.6, 8.9 vs. 13.0%). Pacific women were more than twice as likely to have ER−, PR− and HER2+ cancer than Māori and others (14.2 vs. 6.0%, 6.7%). After adjustment for age, year of diagnosis, stage, grade and treatment, the hazard ratios of breast cancer-specific mortality for Māori and Pacific women with ER+, PR+ and HER2− were 1.52 (95% CI 1.06–2.18) and 1.55 (95% CI 1.04–2.31) compared to others, respectively. Māori women with HER2+ cancer were twice more likely to die of their cancer than others.

Conclusions

Outcomes for Māori and Pacific women could be improved by better treatment regimens especially for those with HER2+ breast cancer and for women with ER+, PR+ and HER2− breast cancer.
Literatur
2.
3.
Zurück zum Zitat Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O’Regan R, Torres MA, Meisel JL (2017) Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161(2):279–287. doi:10.1007/s10549-016-4059-6 CrossRefPubMed Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O’Regan R, Torres MA, Meisel JL (2017) Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161(2):279–287. doi:10.​1007/​s10549-016-4059-6 CrossRefPubMed
4.
Zurück zum Zitat Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36):5652–5657. doi:10.1200/JCO.2006.06.5664 CrossRefPubMed Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36):5652–5657. doi:10.​1200/​JCO.​2006.​06.​5664 CrossRefPubMed
6.
Zurück zum Zitat Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, Albain KS, André F, Bergh J, Bonnefoi H, Bretel-Morales D, Burstein H, Cardoso F, Castiglione-Gertsch M, Coates AS, Colleoni M, Costa A, Curigliano G, Davidson NE, Leo AD, Ejlertsen B, Forbes JF, Gelber RD, Gnant M, Goldhirsch A, Goodwin P, Goss PE, Harris JR, Hayes DF, Hudis CA, Ingle JN, Jassem J, Jiang Z, Karlsson P, Loibl S, Morrow M, Namer M, Osborne CK, Partridge AH, Penault-Llorca F, Perou CM, Piccart-Gebhart MJ, Pritchard KI, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao ZM, Smith I, Thürlimann B, Toi M, Tutt A, Untch M, Viale G, Watanabe T, Wilcken N, Winer EP, Wood WC (2013) Personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013. Ann Oncol 24(9):2206–2223. doi:10.1093/annonc/mdt303 CrossRefPubMedPubMedCentral Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, Albain KS, André F, Bergh J, Bonnefoi H, Bretel-Morales D, Burstein H, Cardoso F, Castiglione-Gertsch M, Coates AS, Colleoni M, Costa A, Curigliano G, Davidson NE, Leo AD, Ejlertsen B, Forbes JF, Gelber RD, Gnant M, Goldhirsch A, Goodwin P, Goss PE, Harris JR, Hayes DF, Hudis CA, Ingle JN, Jassem J, Jiang Z, Karlsson P, Loibl S, Morrow M, Namer M, Osborne CK, Partridge AH, Penault-Llorca F, Perou CM, Piccart-Gebhart MJ, Pritchard KI, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao ZM, Smith I, Thürlimann B, Toi M, Tutt A, Untch M, Viale G, Watanabe T, Wilcken N, Winer EP, Wood WC (2013) Personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013. Ann Oncol 24(9):2206–2223. doi:10.​1093/​annonc/​mdt303 CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329–2334. doi:10.1158/1078-0432.CCR-06-1109 CrossRefPubMed Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329–2334. doi:10.​1158/​1078-0432.​CCR-06-1109 CrossRefPubMed
8.
Zurück zum Zitat Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M (2011) Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365 Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M (2011) Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365
9.
10.
Zurück zum Zitat Metcalfe S, Evans J, Priest G (2007) PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer. N Z Med J 120:(1256) Metcalfe S, Evans J, Priest G (2007) PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer. N Z Med J 120:(1256)
16.
Zurück zum Zitat Earle D (1995) Pacific Islands peoples in Aotearoa/New Zealand: existing and emerging paradigms. Wellington Earle D (1995) Pacific Islands peoples in Aotearoa/New Zealand: existing and emerging paradigms. Wellington
17.
Zurück zum Zitat Campbell I, Scott N, Seneviratne S, Kollias J, Walters D, Taylor C, Roder D (2015) Breast cancer characteristics and survival differences between Maori, Pacific and other New zealand women included in the quality audit program of breast surgeons of Australia and New Zealand. Asian Pac J Cancer Prev 16(6):2465–2472. doi:10.7314/APJCP.2015.16.6.2465 CrossRefPubMed Campbell I, Scott N, Seneviratne S, Kollias J, Walters D, Taylor C, Roder D (2015) Breast cancer characteristics and survival differences between Maori, Pacific and other New zealand women included in the quality audit program of breast surgeons of Australia and New Zealand. Asian Pac J Cancer Prev 16(6):2465–2472. doi:10.​7314/​APJCP.​2015.​16.​6.​2465 CrossRefPubMed
18.
Zurück zum Zitat Davey V, Robinson B, Dijkstra B, Harris G (2012) The Christchurch Breast Cancer Patient Register: the first year. N Z Med J 125(1360):37–47PubMed Davey V, Robinson B, Dijkstra B, Harris G (2012) The Christchurch Breast Cancer Patient Register: the first year. N Z Med J 125(1360):37–47PubMed
19.
Zurück zum Zitat Seneviratne S, Lawrenson R, Scott N, Kim B, Shirley R, Campbell I (2015) Breast cancer biology and ethnic disparities in breast cancer mortality in New Zealand: a cohort study. PLoS ONE 10 (4). doi:10.1371/journal.pone.0123523 Seneviratne S, Lawrenson R, Scott N, Kim B, Shirley R, Campbell I (2015) Breast cancer biology and ethnic disparities in breast cancer mortality in New Zealand: a cohort study. PLoS ONE 10 (4). doi:10.​1371/​journal.​pone.​0123523
20.
Zurück zum Zitat Lawrenson R, Seneviratne S, Scott N, Peni T, Brown C, Campbell I (2016) Breast cancer inequities between Maori and non-Maori women in Aotearoa/New Zealand. Eur J Cancer Care 25(2):225–230. doi:10.1111/ecc.12473 CrossRef Lawrenson R, Seneviratne S, Scott N, Peni T, Brown C, Campbell I (2016) Breast cancer inequities between Maori and non-Maori women in Aotearoa/New Zealand. Eur J Cancer Care 25(2):225–230. doi:10.​1111/​ecc.​12473 CrossRef
22.
Zurück zum Zitat Seneviratne S, Scott N, Lawrenson R, Campbell I (2015) Ethnic, socio-demographic and socio-economic differences in surgical treatment of breast cancer in New Zealand. ANZ J Surg. doi:10.1111/ans.13011 Seneviratne S, Scott N, Lawrenson R, Campbell I (2015) Ethnic, socio-demographic and socio-economic differences in surgical treatment of breast cancer in New Zealand. ANZ J Surg. doi:10.​1111/​ans.​13011
24.
Zurück zum Zitat Tin ST, Elwood JM, Lawrenson R, Campbell I, Harvey V, Seneviratne S (2016) Differences in breast cancer survival between public and private care in New Zealand: which factors contribute? PLoS ONE. doi:10.1371/journal.pone.0153206 Tin ST, Elwood JM, Lawrenson R, Campbell I, Harvey V, Seneviratne S (2016) Differences in breast cancer survival between public and private care in New Zealand: which factors contribute? PLoS ONE. doi:10.​1371/​journal.​pone.​0153206
25.
Zurück zum Zitat Sarfati D, Gurney J, Stanley J, Salmond C, Crampton P, Dennett E, Koea J, Pearce N (2014) Cancer-specific administrative data-based comorbidity indices provided valid alternative to Charlson and National Cancer Institute Indices. J Clin Epidemiol 67(5):586–595. doi:10.1016/j.jclinepi.2013.11.012 CrossRefPubMed Sarfati D, Gurney J, Stanley J, Salmond C, Crampton P, Dennett E, Koea J, Pearce N (2014) Cancer-specific administrative data-based comorbidity indices provided valid alternative to Charlson and National Cancer Institute Indices. J Clin Epidemiol 67(5):586–595. doi:10.​1016/​j.​jclinepi.​2013.​11.​012 CrossRefPubMed
26.
Zurück zum Zitat Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22(8):1736–1747. doi:10.1093/annonc/mdr304 CrossRefPubMedPubMedCentral Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22(8):1736–1747. doi:10.​1093/​annonc/​mdr304 CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796–1804. doi:10.1200/JCO.2011.38.8595 CrossRef Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796–1804. doi:10.​1200/​JCO.​2011.​38.​8595 CrossRef
29.
Zurück zum Zitat Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ (2009) Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. doi:10.1186/bcr2261 PubMedPubMedCentral Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ (2009) Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. doi:10.​1186/​bcr2261 PubMedPubMedCentral
30.
Zurück zum Zitat Huober J, Von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Högel B, Darb-Esfahani S, Mehta K, Loibl S (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124(1):133–140. doi:10.1007/s10549-010-1103-9 CrossRefPubMed Huober J, Von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Högel B, Darb-Esfahani S, Mehta K, Loibl S (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124(1):133–140. doi:10.​1007/​s10549-010-1103-9 CrossRefPubMed
31.
Zurück zum Zitat Seneviratne S, Campbell I, Scott N, Shirley R, Peni T, Lawrenson R (2015) Ethnic differences in breast cancer survival in New Zealand: contributions of differences in screening, treatment, tumor biology, demographics and comorbidities. Cancer Causes Control 26(12):1813–1824. doi:10.1007/s10552-015-0674-5 CrossRefPubMed Seneviratne S, Campbell I, Scott N, Shirley R, Peni T, Lawrenson R (2015) Ethnic differences in breast cancer survival in New Zealand: contributions of differences in screening, treatment, tumor biology, demographics and comorbidities. Cancer Causes Control 26(12):1813–1824. doi:10.​1007/​s10552-015-0674-5 CrossRefPubMed
32.
Zurück zum Zitat Seneviratne S, Lawrenson R, Harvey V, Ramsaroop R, Elwood M, Scott N, Sarfati D, Campbell I (2016) Stage of breast cancer at diagnosis in New Zealand: impacts of socio-demographic factors, breast cancer screening and biology. BMC Cancer 16 (1). doi:10.1186/s12885-016-2177-5 Seneviratne S, Lawrenson R, Harvey V, Ramsaroop R, Elwood M, Scott N, Sarfati D, Campbell I (2016) Stage of breast cancer at diagnosis in New Zealand: impacts of socio-demographic factors, breast cancer screening and biology. BMC Cancer 16 (1). doi:10.​1186/​s12885-016-2177-5
34.
Zurück zum Zitat Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, dos-Santos-Silva I, Ursin G (2017) Parity, hormones and breast cancer subtypes—results from a large nested case-control study in a national screening program. Breast Cancer Res 19(1). doi:10.1186/s13058-016-0798-x Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, dos-Santos-Silva I, Ursin G (2017) Parity, hormones and breast cancer subtypes—results from a large nested case-control study in a national screening program. Breast Cancer Res 19(1). doi:10.​1186/​s13058-016-0798-x
35.
Zurück zum Zitat Agresti R, Meneghini E, Baili P, Minicozzi P, Turco A, Cavallo I, Funaro F, Amash H, Berrino F, Tagliabue E, Sant M (2016) Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study. Breast Cancer Res Treat 157(1):179–189. doi:10.1007/s10549-016-3802-3 CrossRefPubMed Agresti R, Meneghini E, Baili P, Minicozzi P, Turco A, Cavallo I, Funaro F, Amash H, Berrino F, Tagliabue E, Sant M (2016) Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study. Breast Cancer Res Treat 157(1):179–189. doi:10.​1007/​s10549-016-3802-3 CrossRefPubMed
37.
Zurück zum Zitat Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jönsson G, Olsson H, Borg Å, Ringnér M (2010) Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. doi:10.1186/bcr2590 Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jönsson G, Olsson H, Borg Å, Ringnér M (2010) Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. doi:10.​1186/​bcr2590
38.
Zurück zum Zitat Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Stefanick ML, Vitolins M, Kabat GC, Rohan TE, Li CI (2011) Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 103(6):470–477. doi:10.1093/jnci/djr030 CrossRefPubMedPubMedCentral Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Stefanick ML, Vitolins M, Kabat GC, Rohan TE, Li CI (2011) Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 103(6):470–477. doi:10.​1093/​jnci/​djr030 CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Ministry of Health (2016) Annual update of key results 2015/16: New Zealand Health Survey. Ministry of Health, Wellington Ministry of Health (2016) Annual update of key results 2015/16: New Zealand Health Survey. Ministry of Health, Wellington
41.
Zurück zum Zitat Lawrenson R, Lao C, Campbell I, Harvey V, Brown C, Seneviratne S, Edwards M, Elwood M, Kuper-Hommel M (2017) The use of trastuzumab in New Zealand women with breast cancer. Asia Pac J Clin Oncol. doi:10.1111/ajco.12766 PubMed Lawrenson R, Lao C, Campbell I, Harvey V, Brown C, Seneviratne S, Edwards M, Elwood M, Kuper-Hommel M (2017) The use of trastuzumab in New Zealand women with breast cancer. Asia Pac J Clin Oncol. doi:10.​1111/​ajco.​12766 PubMed
Metadaten
Titel
Treatment and survival disparities by ethnicity in New Zealand women with stage I–III breast cancer tumour subtypes
verfasst von
Ross Lawrenson
Chunhuan Lao
Ian Campbell
Vernon Harvey
Sanjeewa Seneviratne
Melissa Edwards
Mark Elwood
Nina Scott
Jacquie Kidd
Diana Sarfati
Marion Kuper-Hommel
Publikationsdatum
13.10.2017
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 12/2017
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-017-0969-9

Weitere Artikel der Ausgabe 12/2017

Cancer Causes & Control 12/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.